An investment towards mass producing mRNA vaccines in Canada.
Federal officials announced Tuesday $402 million will be put towards the initiative, including $200 million going into Resilience Biotechnologies of Mississauga, where vaccines will be produced.
“Once completed, the new facility is expected to be able to manufacture between 112 million and 620 million doses of mRNA vaccines per year, a significant boost to our domestic capacity,” explained Minister of Innovation, Science and Industry, Francois-Phillipe Champagne. “This will position Canada well to attract vaccine manufacturing for both the Canadian market and the export market. This investment is good news for Mississauga, good news for Ontario, and good news for the growing life sciences ecosystem all across Canada.”
Canada has had to rely on internationally produced vaccines throughout the COVID-19 pandemic.
“An investment of almost $200 million in Resilience Biotechnologies will not only boost Canadian manufacturing, but will also support good Canadian jobs,” remarked Prime Minister Justin Trudeau. “This funding will maintain and create 500 well paying full-time jobs at the Resilience facility in Mississauga, positions that people can rely on to provide for their families. It will also mean 50 co-op spots which well help young people get their foot in the door in a growing sector.”
